Plasmacure Highlights Cold Plasma Wound Therapy Use in Resource-Limited Setting

According to a recent LinkedIn post from Plasmacure, the company’s cold plasma therapy device PLASOMA has been used in a low‑income clinical setting on Sint Maarten, a Caribbean island with high wound complexity and limited advanced care options. The post highlights that many treated diabetic foot ulcers had been open for more than a year, were often moderately to severely infected, and had limited revascularization possibilities.

The LinkedIn post suggests that, despite these constraints, PLASOMA was associated with what the company describes as “remarkable progress” and “powerful” results in these long‑standing cases. For investors, this field‑use narrative may indicate potential for the technology in underserved markets and complex wound indications, which could expand the addressable market and strengthen Plasmacure’s positioning in advanced wound care if such outcomes are replicated and supported by formal clinical and economic data.